Press release news from the public relations clients of Tiziani Whitmyre, Inc.
December 3rd, 2013
NoInjuries.com Launches to Help Prevent Injuries to Caregivers and Patients in Healthcare Facilities
Lehigh Valley, Penn. –December 3, 2013 — Recognizing the growing volume of injuries occurring in healthcare facilities each day, a new Web portal — NoInjuries.com — launches today, aimed at improving the personal safety of caregivers and patients.
“Healthcare is the largest and fastest-growing sector of the U.S. economy, employing approximately 17 million workers. But virtually everyone involved in healthcare is susceptible to a startling array of safety hazards,” said Hans Sigvardsson, president of Handicare US, the sponsor of the NoInjuries.com initiative.
“We are supporting NoInjuries.com to raise awareness and help reduce both the number and severity of injuries in healthcare facilities — and to eliminate the pain, suffering, and associated costs of those injuries,” Sigvardsson said.
“We believe that the vast majority of healthcare-related injuries are preventable. The key is to gain the personal buy-in of all involved individuals to support injury reduction efforts. NoInjuries.com is aimed at focusing attention on the problem and providing education and resources to stimulate and support that commitment,” he said
NoInjuries.com will reach caregivers such as nurses, physicians, therapists, and other dedicated healthcare providers, with a vast array of continually up-to-date news, educational materials, easy-to-implement tips, and tools and resources to use throughout the workplace. The portal will focus on six critical hazard areas:
- Patient Handling
- Sharps & Sticks
- Slips & Falls
- Workplace Violence
- Patient Safety
“Workplace injuries can happen anywhere — and everywhere — in emergency rooms, operating rooms, diagnostic areas, waiting rooms, and even in corridors,” Sigvardsson said. “It is our mission — through NoInjuries.com — to make ‘No Injuries’ a reality for patients, caregivers, and throughout the healthcare industry.”
For more information on the NoInjuries.com initiative, visit the Website at http://www.NoInjuries.com.
About Handicare AS
Handicare AS was founded in 1986 and supplies safe handling and mobility solutions for hospital patients, elderly residents, and physically disabled individuals. Its products include wheelchairs, patient lifts, stairlifts, mobility equipment, bathroom safety products, and personal transfer and automobile adaptation solutions. Handicare products are distributed through a comprehensive network of professional dealers and distributors in 30 countries around the world. The company has subsidiaries in Sweden, Denmark, Germany, the Netherlands, England, Belgium, France, the USA, and Canada. For more information, visit the Handicare website at http://www.handicare.com.
About Handicare United States
Handicare US is headquartered in Allentown, Pennsylvania, and works with over 400 partners nationally to provide Safe Patient Handling, Mobility and Accessibility equipment to people with disabilities, aging and elderly individuals residing at home or in hospitals and nursing homes. With significant growth over the past year, Handicare US is well positioned to assume leadership roles in safe patient handling and improved patient outcomes, both of which are areas of strategic concern for healthcare administrators and caregivers.
The company’s wide range of high-quality products include: Complete easy transfer systems and other patient handling aids, walkers, stairlifts, and bathing and toileting products. In 2012, RoMedic, Inc. (Ephrata, PA) and Sterling Stairlifts (Pocono Mountain, PA) merged to form the Handicare US division and provide solutions and support that allow people to work and live safely and independently.
December 3rd, 2013
AGAWAM, MASS. — December 3, 2013 — Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, is adding OECD Fish Embryo Toxicity Testing to its portfolio of services.
Pharmaceutical, chemical, and related manufacturing plants are under increased scrutiny for the potential impact of their products or waste water on the environment. Pesticides are a major example. But recently, the European Commission added three pharmaceutical compounds to its pollutant watch list, citing them as potential risk to the safety of surface water.
“Fish Embryo Toxicity (FET) testing has been developed for environmental and hazard classification applications. The test utilizes the embryo of the Zebrafish and exposes it to various compounds to observe potential toxic effects, thus making FET an ideal method to use in monitoring or investigating environmental cases,” said Steven Richter, Ph.D., president and scientific director of Microtest Laboratories — and former FDA official.
The FET test is an approved OECD (Organization for Economic Co-Operative Development) guideline, published in August, 2013.
““Microtest Laboratories is deeply experienced in fish embryo toxicity testing. We are particularly well-suited to undertake FET testing due to the expertise we’ve developed in creating our Zebrafish Embryo Toxicity (ZET) test, which we’ve been providing as a preliminary screening method in the biocompatibility testing of medical devices and polymers.
“Zebrafish embryos are extensively used in drug development studies due to their transparent embryos and fast development times. The Zebrafish is a well-studied and characterized organism, and ideal as an animal testing model,” Richter noted.
For more information about Microtest Laboratories’ FET testing services, visit http://www.microtestlabs.com/zebrafish-embryos-testing. Or, call 1-413-786-1680 or toll-free at 1-800-631-1680.
In addition, a new whitepaper provides an overview of FET testing. Download “Fish Embryo Toxicology Testing: The Better Alternative for Whole-Effluent Testing” from: http://microtestlabs.com/fish-embryo-toxicology-testing.
About Microtest Laboratories
Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free at 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.
# # #
Download high-resolution photos for publication from: http://flic.kr/s/aHsjNs2t58
November 19th, 2013
Needham, MA — November 19, 2013 –– Environmental Health & Engineering, Inc. (EH&E), a leading provider of environmental and engineering consulting services to the property management, healthcare, research, and biopharma industries, has been named one of The Boston Globe’s Top Places to Work for 2013.
The Boston Globe’s 2013 Top Places to Work survey recognizes the most progressive companies in Massachusetts, based on employees’ opinions of key factors related to employee happiness including leadership, appreciation, career opportunities, compensation, and management practices in their organizations. This year’s results are based on a survey of 76,000 employees.
“EH&E is an employee-owned company and our people drive the growth and success of our company,” says John McCarthy, President and co-founder of EH&E. “They are passionate about their work and committed to providing customers with exceptional service. In our 25th year, it is rewarding that their enthusiasm has earned us the distinction of being one of the best places to work in Boston.
EH&E helps businesses and institutions optimize their work environment, environmental compliance programs and building performance to prevent disruptions to vital operations and to maximize alignment with business goals. EH&E has worked with distinguished national organizations and agencies including the US Environmental Protection Agency, Brigham and Women’s Hospital, Massachusetts Institute of Technology, Putnam Investments, Steward Health Care Network, The Broad Institute and Partners Healthcare. Our professional scientific and engineering staff provides expertise in over 80 technical disciplines, and includes internationally recognized experts in many scientific fields. EH&E brings innovative and sound scientific solutions to each business challenge our clients face. EH&E is based in Neeham, Mass. Visit our website at http://www.eheinc.com.
November 12th, 2013
Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston
AGAWAM, MASS. — November 12, 2013 — A half-day seminar focusing on current regulatory expectations in the validation of reusable medical devices is the subject of a seminar set for Dec. 4th in Waltham, Mass., near Boston.
The validation of reusable medical devices is at the forefront of the FDA’s efforts to ensure patient safety. Requirements for the cleaning, disinfection, and sterilization of reusable devices are constantly changing. The situation challenges manufacturers both in terms of deciding which testing methods to employ as well as the planning of end points.
The seminar will provide attendees with the knowledge they need to know about current regulatory expectations so they may better prepare their submissions for FDA acceptance — and avoid the time-consuming and costly requirements of additional testing.
Seminar topics will include:
- Discussion of the FDA’s draft guidance for industry and FDA staff, “Processing/ Preprocessing Medical Devices in Healthcare Settings”
- Methods used for the cleaning and validation of reusable devices
- Methods for the disinfection of reusable devices
- Methods for the sterilization of reusable devices
- Testing requirements
- Detailed discussion of endpoints for cleaning validation
The seminar will be presented by Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries, on Wednesday, Dec. 4, 2013, from 9 a.m. to 1 p.m. at the Conference Center at Waltham Woods in Waltham, Mass., just outside Boston. Registration is at 9 a.m. A continental breakfast, break refreshments, and a luncheon are included.
About Microtest Laboratories
Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Facebook at http://facebook.com/MicrotestLaboratories, on LinkedIn at http://goo.gl/H8ZLnM or on Twitter @MicrotestLabs.
November 5th, 2013
AGAWAM, MASS. – Nov. 5, 2013 – The strategies and timing of outsourcing pharmaceutical development processes to a contract testing laboratory will be the focus of a mini-workshop at the 2013 AAPS Annual Meeting and Exposition on Nov. 12, 2013.
“Outsourcing to a contract testing laboratory can save pharmaceutical manufacturers both time and money in drug development and commercialization. But knowing the appropriate time and place to outsource can mean the difference between success and failure,” said Shawn Sherry of Microtest Laboratories.
At the mini-workshop, titled “Outsourcing to a Contract Testing Laboratory,” Sherry will overview:
- The benefits of using turnkey contract laboratory services
- How to establish a smooth working relationship with your laboratory
- The importance of the auditing process
- Quality system, timeline, and pricing factors
- How Microtest Laboratories can help
The mini-workshop will be presented Nov. 12th from 2:00 p.m. to 2:15 p.m. in the Microtest Laboratories booth, #1325, at the AAPS 2013 Annual Exposition.
Shawn Sherry, Account Development Manager at Microtest Laboratories Inc., has over 11 years’ experience in regulatory microbiology and contract laboratory operations. Sherry holds a BS degree in microbiology and is a nationally registered microbiologist. His experience ranges from compendia testing requirements to aseptic manufacturing, with emphasis on disinfectant qualifications, clean room testing, product testing, and water system validations. He is the co-author of the whitepaper, “Disinfectant Qualifications: Insight and Perspective,” available at http://www.microtestlabs.com/disinfectant-qualifications.
Microtest Laboratories will exhibit in booth #1325 throughout the 2013 AAPS Annual Meeting and Exposition. Microtest Labs is a leader in pharmaceutical contract manufacturing as well as microbiological, analytical, and cleanroom testing services. The company services the pharmaceutical, medical device, and biotechnology industries. Based in Agawam, Mass., Microtest’s testing facilities are ISO 9001 and ISO 17025 certified, FDA regulated, and meet all GLP/GMP standards. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.
# # #
October 22nd, 2013
Honeywell Safety Products Introduces New Max® Small Pink Earplugs for People With Smaller Ear Canals
SMITHFIELD, R.I., Oct. 22, 2013 — Honeywell (NYSE: HON) today introduced new MAX® Small Pink earplugs — a bright pink version of its popular orange MAX Small single-use earplug for people with smaller ear canals.
MAX Small earplugs were introduced in 2011 in response to reports from people with smaller ear canals about having trouble obtaining a good fit — and adequate protection — from other high-attenuating roll-down foam earplugs. Since the launch, user feedback about MAX Small has included requests for a version in pink.
In response, a new pink version, MAX Small Pink, has been introduced and is available now for a limited time only. MAX Small Pink earplugs features include:
- The same bell shape and patented varied-cell polyurethane foam as the standard Howard Leight® MAX earplug — but are 20% smaller in volume;
- A reduced size that offers workers with smaller ear canals a better and more comfortable fit;
- A higher attenuation (NRR 30) than other larger single-use earplugs.
MAX Small Pink is available now, in both corded and uncorded models, from industrial safety distributors in the U.S. and Canada.
For more information about MAX, MAX Small, and MAX Small Pink earplugs, visit http://www.howardleight.com. High resolution images of MAX Small Pink earplugs are available for download from: http://goo.gl/rqsLnE and http://goo.gl/bdL9xo.
About Honeywell Safety Products
Honeywell Safety Products (HSP), a global manufacturer of leading personal protective equipment (PPE) and provider of safety solutions, helps company employees make safer decisions on their own and build an enduring culture of safety. With world class brands such as Honeywell®, Uvex®, North®, Howard Leight®, Miller®, Fibre-Metal® and Servus®, HSP offers a full range of quality PPE, including: protective clothing; fall and hearing protection products; solutions that protect hands, head, feet, eyes and face; along with respiratory, welding, first-aid, lockout/tagout and traffic safety equipment. Lead them to safety—visit www.honeywellsafety.com/culture to learn more.
Honeywell (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; turbochargers; and performance materials. Based in Morris Township, N.J., Honeywell’s shares are traded on the New York, London, and Chicago Stock Exchanges. For more news and information on Honeywell, please visit www.honeywellnow.com.
This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address activities, events or developments that we or our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this release are also subject to a number of material risks and uncertainties, including but not limited to economic, competitive, governmental, and technological factors affecting our operations, markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by such forward-looking statements. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.
Tags: ear plugs, earplugs, hearing conservation, hearing proection, hearing protection solutions, Honeywell, howard leight, NIHL, noise-induced hearing loss, personal protective equipment, PPE, worker safety
October 22nd, 2013
Use of Stability Studies in Drug, Combination Products & Medical Device Development are Reviewed in New Whitepaper
AGAWAM, MASS. — October 22, 2013 —The use of stability testing in new product development — of drug substances, drug products, combination products and some medical devices — is reviewed in a new whitepaper from Microtest Laboratories, a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries.
The paper, “The Use of Stability Studies in Pharmaceutical and Combination Product Development” (download from: http://microtestlabs.com/stability-studies), outlines how stability studies can be used to gather valuable information about a new product and prevent unnecessary manufacturing costs and time delays.
Stability studies can help determine formulation and manufacturing strategy, analytical assay development and validation — and help explain unexpected and failing results. They can also provide input to manufacturing controls, and help identify final packaging requirements. The paper examines three specialized stability studies as examples:
- Forced degradation studies, which involve exposing the product to predetermined stress conditions in order to intentionally form likely degradation products;
- Photostability testing, used to determine the product’s ability to withstand exposure to light without any adverse effects;
- Temperature cycling studies, used to assess the impact of temperature changes on the product.
Two case studies, one involving a drug product and one a combination product, are also presented.
The use of stability studies in the development of new drug or combination products can ease both the planning and execution of a development strategy. Moreover, the studies may also help prevent unnecessary costs and time delays due to poor formulations, assay failures, and manufacturing problems.
Download the new whitepaper, “The Use of Stability Studies in Pharmaceutical and Combination Product Development,” from: http://microtestlabs.com/stability-studies.
About Microtest Laboratories
Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.
October 15th, 2013
Maryland Oncology Hematology Employs Medica’s EasyRA Clinical Chemistry Analyzer to Improve Lab Efficiency, Reduce Cost: Case Study
BEDFORD, Mass. — Oct. 15, 2013 — A case study details how Maryland Oncology Hematology is employing Medica’s EasyRA® Clinical Chemistry Analyzer to increase efficiency and reduce costs at its on-site clinical laboratory — while improving overall patient care.
[Download the case study from the Medica website at http://www.medicacorp.com/resources/easyra-clinical-chemistry-system.]
Maryland Oncology Hematology in Columbia, Md. is a full-service outpatient cancer treatment and testing facility. Visited by 80 to 100 patients a day, the practice provides a variety of cancer treatment therapies including chemotherapy, infusion therapy, injections, and therapeutic phlebotomies. The practice houses a state-accredited clinical laboratory that provides convenient and immediate testing results for patient convenience.
A routine yet essential service performed by many medical centers across the country, including Maryland Oncology Hematology, is the testing of blood samples. Lab technicians work with the patient and their doctor to administer and review blood test results to better guide treatment.
When Maryland Oncology Hematology moved to a new and larger facility, and established a new onsite clinical lab, the practice identified clinical chemistry as work that could be performed in-house. Lab Director Kendra Davies evaluated bench top clinical chemistry analyzers that would meet their four-person lab’s needs and which could be integrated with the lab’s workflow — without requiring additional staffing.
Based on interviews with Davies, the case study reviews how Maryland Oncology Hematology selected and now employs Medica Corporation’s EasyRA chemistry analyzer to realize greater laboratory efficiency and coordination of patient tests, while reducing overall cost. From shorter turnaround time to improved patient care, the case details how the EasyRA chemistry analyzer transformed the way Maryland Oncology Hematology conducted its day-to-day lab Chemistry workload.
Download the case study from the Medica website at http://www.medicacorp.com/resources/easyra-clinical-chemistry-system.
About Medica Corporation
Medica Corporation is a leading provider of easy-to-use, easy-to-maintain, low-cost blood testing analyzers. Based in Bedford, Massachusetts, U.S.A., the company is focused on the global need to reduce the cost and improve the quality of health care. Medica’s products include the EasyLyte®, ISE Module, EasyBloodGas™, EasyElectrolytes™, EasyStat®, EasyRA® and EasyCell® assistant analyzers. For more information, visit http://www.medicacorp.com.
The Medica logo and EasyRA® are registered trademarks of Medica Corporation or its subsidiaries and affiliated companies. All other brands may be trademarks of their respective holders.
October 15th, 2013
Immunetics Introduces Updated BacTx Analyzer for Use with its BacTx Rapid Test for Bacterial Contamination of Platelets
Boston, MA — October 14, 2013 — Immunetics, Inc., a leading clinical test provider, today introduced the updated BacTx® Analyzer for use with its BacTx rapid test for bacteria in whole-blood derived and apheresis platelets. The Analyzer offers automated interpretation, tracking, and documentation — features that not only increase transfusion patient safety, but also provide seamless integration with the laboratory workplace.
The BacTx assay gives hospitals and blood banks a practical tool for assuring the safety of their platelets. The colorimetric assay can detect aerobic, anaerobic, gram-negative and gram-positive bacteria in a single test. The test is designed to enable testing closer to time of transfusion, to reduce the risk of transfusing contaminated platelets.
The updated BacTx Analyzer delivers a faster turnaround of results and a host of new automation and workflow-enhancement features. Complete assay results and analysis are delivered within 30 minutes. STAT, control, and standard assay capabilities allow for testing flexibility. Designed for simple, easy integration, the BacTx Analyzer fits seamlessly into the existing workflow of any laboratory or transfusion center.
“Today, the bacterial contamination of platelets represents a significant risk to the highly vulnerable patients that require transfusions. Existing approaches to detecting bacteria have fallen short, and the industry’s need for an effective, low-cost testing technology is greater than ever,” said John Yonkin, Chief Executive Officer of Immunetics. “Highly sensitive, specific bacterial detection, as provided by the BacTx rapid test with the BacTx Analyzer, helps improve the quality of patient care.”
Features of the updated BacTx Analyzer include:
• Easy and efficient sample preparation;
• Bar code scanning to minimize user input error and maximize efficiency;
• Random access testing that allows multiple assays to be run at different times;
• LED touch screen to simplify operation;
• Logical workflow to accelerate users’ learning curves;
• Passcode and user ID entry that adds security during testing;
• Visual confirmation on both the analyzer and touch screen for best-practice quality control (QC), tracking, and platelet management;
• Automated tracking of tests, trends, and QC;
• USB port for quick and easy download of data
• Small footprint for crowded, cramped lab space.
The BacTx system utilizes a patented, highly specific, universal bacterial detection reagent that has been shown to detect wild and cultured bacterial strains. The assay meets AABB standard 184.108.40.206.1. and can be used for quality-control testing of:
• Leukocyte-reduced apheresis platelets (LRAP) within 24 hours of transfusion, following testing with an FDA-cleared growth-based bacterial detection device.
• Pools of up to six units of leukocyte-reduced whole-blood derived platelets that are pooled within 4 hours of transfusion.
For more information on the BacTx Rapid Assay System, visit the Immunetics Website at http://immunetics.com/bactx.html or contact Immunetics at 1-617-896-9100 or toll-free at 1-800-227-4765. Immunetics will be displaying the BacTx System at the AABB Annual Meeting and CTTXPO in Booth #527.
Immunetics, Inc. offers state-of-the-art assay technology for infectious disease diagnosis and blood screening, and for more than 10 years, has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. The company has issued patents on its BacTx test for bacterial contamination of platelets. It has developed and markets other FDA-cleared products, including a test for Lyme disease, and is actively working on new tests for Babesiosis and Chagas disease — both of which are emerging risks to the blood supply. Immunetics is headquartered in Boston, Massachusetts. The company’s mission is to deliver better cost-efficient care through more accurate diagnosis. For more information, visit the Immunetics website at http://immunetics.com.
BacTx® is a registered trademark of Immunetics, Inc.
October 3rd, 2013
FLORHAM PARK, NEW JERSEY, USA, October 3, 2013 – ASCO Numatics, the world’s leading manufacturer of comprehensive fluid automation, flow control, and pneumatics solutions, announced the recipients of the 2013 ASCO Numatics Industrial Automation Engineering Scholarship.
The recipients, William (Daniel) Whitten, of Tulsa, Okla., a junior at Texas A&M University in College Station, Texas; and Meghan Borz, of Buena, N.J., a senior at Rowan Unversity in Glassboro, N.J., were each awarded a $5,000 scholarship from ASCO Numatics towards their Bachelor’s program degrees in mechanical engineering.
ASCO Numatics will further support their studies with an additional $1,000 grant to the engineering departments at each of their universities.
“Engineers apply creativity and skills to transform innovation into reality. The ASCO Numatics scholarship program applies that same spirit by helping support leading students in their education to become the next generation leaders in industry and technology,” said Robert W. Kemple, Jr., executive vice president, sales and marketing – Americas, ASCO Numatics. “We are proud to support Mr. Whitten and Ms. Borz as they prepare for their future careers.”
ASCO Numatics announced the scholarship winners at PMMI’s annual 2013 Amazing Packaging Race at PACK EXPO 2013 in Las Vegas. The two students were guests at the Expo, courtesy of ASCO Numatics.
Sponsored by ASCO Numatics, the Amazing Packaging Race is a fun and educational event that pits teams of packaging students, from programs around the country, against each other in a race to gather points by completing tasks at specific PACK EXPO booths. ASCO Numatics’ sponsorship of the race helps support the PMMI Education and Training Foundation, which provides scholarships to packaging students from PMMI partner schools.
The ASCO Numatics Industrial Automation Engineering Scholarship program, now in its sixth year, has awarded a total of $60,000 in merit-based scholarships to 12 students, based on their potential for leadership and for making a significant contribution to the industrial automation engineering profession, particularly as it relates to the application of fluid control and fluid power technologies. The company has provided an additional $12,000 in grants to 10 schools of engineering. For information on the program, visit www.asconumatics.com/scholarship.
About ASCO Numatics
ASCO Numatics, an Emerson company, offers comprehensive fluid automation solutions, including fluid control and fluid power products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit www.asconumatics.com.
Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets around the world. The company is comprised of five business segments: Process Management, Industrial Automation, Network Power, Climate Technologies, and Commercial & Residential Solutions. Sales in fiscal 2012 were $24.4 billion. For more information, visit www.Emerson.com.
B2B News is proudly powered by WordPress.
About Tiziani Whitmyre
Tiziani Whitmyre Inc.'s public relations expertise is in technology & life sciences PR. We work with companies from small business startups to global leaders. Unlike traditional firms, we are very flexible in our PR services and combine the expertise of large agency professional talent within the flexibility of a boutique. We help clients generate sales leads, launch new products, enter new markets, establish technical leadership, and achieve other business goals. We craft and execute cost-effective, results-focused efforts that integrate traditional and Web 2.0 solutions as discrete projects, targeted campaigns, on-going PR programs, or elements in an integrated marketing program. Our industry experience is deep and includes analytical instruments, biotechnology, ecommerce, food and dairy, healthcare, high technology, laboratory sciences, life sciences, machinery, manufacturing, medical products, pharmaceuticals, professional services, and software